Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.63), $0.23 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $3.58 million versus the consensus estimate of $2.15 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.